MAXCYTE, INC.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)


· Three Months Ended September 30, · Nine Months Ended September 30,
· · 2025 · 2024 · · 2025 · 2024
Revenue	$6,829	$8,164	$25,726	$29,934
Cost of goods sold	1,596	1,928	4,612	4,819
Gross profit	5,233	6,236	21,114	25,115

Operating expenses:
Research and development	5,316	5,316	17,488	17,613
Sales and marketing	3,936	6,207	15,420	20,188
General and administrative	6,028	7,745	22,634	22,487
Restructuring expense	3,058	—	3,058	—
Depreciation and amortization	1,044	1,021	3,185	3,123
Total operating expenses	19,382	20,289	61,785	63,411
Operating loss	(14,149)	(14,053)	(40,671)	(38,296)

Other income:
Interest income	1,733	2,496	5,637	7,838
Total other income	1,733	2,496	5,637	7,838
Loss before income taxes	(12,416)	(11,557)	(35,034)	(30,458)
Provision for income taxes	—	—	—	—
Net loss	$(12,416)	$(11,557)	$(35,034)	$(30,458)
Basic and diluted net loss per share	$(0.12)	$(0.11)	$(0.33)	$(0.29)
Weighted-average shares outstanding, basic and diluted	106,613,075	105,109,603	106,324,792	104,614,679

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.